(Q41445495)

30 September 2017

1 reference

title

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity (English)

1 reference

30 September 2017

0 references

R Davis

1

1 reference

PubMed ID

9118819

30 September 2017

D Faulds

series ordinal

2

1 reference

30 September 2017

1 November 1996

1 reference

30 September 2017

1 reference

30 September 2017

52

1 reference

30 September 2017

696-724

1 reference

30 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199652050-00007

30 September 2017

0 references

cites work

Current views on obesity

1 reference

12 December 2020

Dexfenfluramine in type II diabetes: effect on weight and diabetes control.

1 reference

12 December 2020

Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis

1 reference

12 December 2020

Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus

1 reference

12 December 2020

Obesity in Europe: prevalence and consequences for use of medical care.

1 reference

12 December 2020

Chronic D-fenfluramine decreases serotonin transporter messenger RNA expression in dorsal raphe nucleus

1 reference

12 December 2020

Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine

1 reference

12 December 2020

Effects of tianeptine on 5-HTP- and dextrofenfluramine-induced hypophagia in the rat.

1 reference

12 December 2020

Long-term weight loss: the effect of pharmacologic agents

1 reference

12 December 2020

The NAASO position paper on approval and use of drugs to treat obesity

1 reference

12 December 2020

Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice

1 reference

12 December 2020

Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour

1 reference

12 December 2020

Severe pulmonary hypertension complicating a long treatment with dexfenfluramine

1 reference

12 December 2020

Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up

1 reference

12 December 2020

The economics of treating obesity

1 reference

12 December 2020

Genetics of obesity in adult adoptees and their biological siblings

1 reference

12 December 2020

The role of dexfenfluramine in the regulation of energy balance. Introduction

1 reference

12 December 2020

d-Fenfluramine selectively decreases carbohydrate but not protein intake in obese subjects

1 reference

12 December 2020

d-Fenfluramine- and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors.

1 reference

12 December 2020

Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers.

1 reference

12 December 2020

Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women

1 reference

12 December 2020

Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction.

1 reference

12 December 2020

Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control

1 reference

12 December 2020

Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated.

1 reference

12 December 2020

Pharmacological aspects of obesity treatment: towards the 21st century

1 reference

12 December 2020

Comparison of medically supervised and unsupervised approaches to weight loss and control

1 reference

12 December 2020

Lipostatic and ischymetric mechanisms originate dexfenfluramine-induced anorexia.

1 reference

12 December 2020

Neurochemical mechanism of action of anorectic drugs

1 reference

12 December 2020

Changes in energy metabolism and metabolite patterns of obese rats after application of dexfenfluramine

1 reference

12 December 2020

Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample

1 reference

12 December 2020

A case of chronic pulmonary hypertension after fenfluramine intake

1 reference

12 December 2020

Socioeconomic consequences of obesity: the effect of obesity on the individual

1 reference

12 December 2020

The Body-Mass Index of Twins Who Have Been Reared Apart

1 reference

12 December 2020

Pulmonary hypertension and fenfluramine

1 reference

12 December 2020

Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates

1 reference

12 December 2020

Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms

1 reference

12 December 2020

Use and abuse of appetite-suppressant drugs in the treatment of obesity

1 reference

12 December 2020

Carbohydrate craving, mood changes, and obesity

1 reference

12 December 2020

Primary pulmonary hypertension and fenfluramine use

1 reference

12 December 2020

The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study

1 reference

12 December 2020

The comparison of four weight reduction strategies aimed at overweight diabetic patients.

1 reference

12 December 2020

Species differences in the kinetics and metabolism of fenfluramine isomers.

1 reference

12 December 2020

The cost of obesity: the Australian perspective

1 reference

12 December 2020

Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man

1 reference

12 December 2020

Regulation of nutrient metabolism and energy expenditure

1 reference

12 December 2020

Measurements of total energy expenditure provide insights into the validity of dietary measurements of energy intake.

1 reference

12 December 2020

Prevalence of obesity: a comparative survey in France, the United Kingdom and the United States

1 reference

12 December 2020

The pharmacokinetics of dexfenfluramine in obese and non-obese subjects

1 reference

12 December 2020

Fenfluramine--induced irreversible pulmonary hypertension

1 reference

12 December 2020

The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks

1 reference

12 December 2020

Dexfenfluramine. Its place in weight control

1 reference

12 December 2020

Effect of dexfenfluramine on energy expenditure in obese patients on a very-low-calorie-diet

1 reference

12 December 2020

Very low-calorie diets. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health

1 reference

12 December 2020

Appetite suppressants. A review

1 reference

12 December 2020

Diet, behavior modification, and exercise: a review of obesity treatments from a long-term perspective

1 reference

12 December 2020

The Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes

1 reference

12 December 2020

Dexfenfluramine neurotoxicity in brains of non-human primates.

1 reference

12 December 2020

Limitations in the assessment of dietary energy intake by self-report

1 reference

12 December 2020

Do serotoninergic drugs decrease energy intake by reducing fat or carbohydrate intake? Effect of d-fenfluramine with supplemented weight-increasing diets.

1 reference

12 December 2020

Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

1 reference

12 December 2020

The cost of obesity: the US perspective

1 reference

12 December 2020

Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system

1 reference

12 December 2020

Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women

1 reference

12 December 2020

Appetite regulation by serotoninergic mechanisms and effects of d-fenfluramine

1 reference

12 December 2020

Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients.

1 reference

12 December 2020

d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects

1 reference

12 December 2020

Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients

1 reference

12 December 2020

Dexfenfluramine and neurotoxicity

1 reference

12 December 2020

Feeding pattern studies suggest that d-fenfluramine and sertraline specifically enhance the state of satiety in rats

1 reference

12 December 2020

Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat

1 reference

12 December 2020

Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals

1 reference

12 December 2020

Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity

1 reference

12 December 2020

Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Effects of chronic low doses of d-fenfluramine on weight gain and calorie intake, brown adipose tissue thermogenic parameters and brain neurotransmitter content in rats fed chow or palatable diets

1 reference

12 December 2020

Dexfenfluramine and appetite in humans

1 reference

12 December 2020

The 5-HT1B receptor mediates the effect of d-fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y

1 reference

12 December 2020

Serotonin and appetite

1 reference

12 December 2020

Epidemiological data on hyperinsulinaemia and vascular disease

1 reference

12 December 2020

Body weight evolution during dexfenfluramine treatment after initial weight control

1 reference

12 December 2020

5-HT and carbohydrate suppression: effects of 5-HT antagonists on the action of d-fenfluramine and DOI.

1 reference

12 December 2020

The interactions of MK-801 with the amphetamine analogues D-methamphetamine (D-METH), 3,4-methylenedioxymethamphetamine (D-MDMA) or D-fenfluramine (D-FEN): neural damage and neural protection.

1 reference

12 December 2020

Obesity drug renews toxicity debate

1 reference

12 December 2020

Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days

1 reference

12 December 2020

An update on the pharmacology of serotoninergic appetite-suppressive drugs

1 reference

12 December 2020

Enhancement of the thermic effect of food by d-fenfluramine

1 reference

12 December 2020

Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet in obese women.

1 reference

12 December 2020

International trial of long-term dexfenfluramine in obesity.

1 reference

12 December 2020

Effect of dexfenfluramine on gastric emptying of a mixed solid-liquid meal in obese subjects

1 reference

12 December 2020

Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991

1 reference

12 December 2020

Serotoninergic receptor activation by dextrofenfluramine enhances the blunted pituitary-adrenal responsiveness to corticotropin-releasing hormone in obese subjects

1 reference

12 December 2020

Dexfenfluramine and neurotoxicity

1 reference

12 December 2020

d-Fenfluramine and d-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release

1 reference

12 December 2020

Drug therapy after very-low-calorie diets.

1 reference

12 December 2020

Serotonin and the biology of feeding

1 reference

12 December 2020

In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia

1 reference

12 December 2020

The International Primary Pulmonary Hypertension Study (IPPHS)

1 reference

12 December 2020

Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study

1 reference

12 December 2020

Endocrine and metabolic effects of dexfenfluramine in patients with android obesity

1 reference

12 December 2020

Neuroendocrine regulation and obesity

1 reference

12 December 2020

The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people

1 reference

12 December 2020

Effect of escalating doses of d-fenfluramine on the content of indoles in brain

1 reference

12 December 2020

Sustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with D-fenfluramine

1 reference

12 December 2020

An Adoption Study of Human Obesity

1 reference

12 December 2020

In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat

1 reference

12 December 2020

Serotonin and dietary fat intake: effects of dexfenfluramine

1 reference

12 December 2020

Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.

1 reference

12 December 2020

Effect of dexfenfluramine on energy expenditure in man

1 reference

12 December 2020

Report on the NIH Workshop on Pharmacologic Treatment of Obesity

1 reference

12 December 2020

The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity

1 reference

12 December 2020

Pulmonary hypertension and dexfenfluramine

1 reference

12 December 2020

Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss

1 reference

12 December 2020

Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline

1 reference

12 December 2020

Metabolic abnormalities linked to obesity: effects of dexfenfluramine in the corpulent rat.

1 reference

12 December 2020

Guidelines for the approval and use of drugs to treat obesity. A position paper of The North American Association for the Study of Obesity

1 reference

12 December 2020

Management strategies for weight control. Eating, exercise and behaviour

1 reference

12 December 2020

Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats

1 reference

12 December 2020

d-fenfluramine in a rat model of dietary fat-induced obesity

1 reference

12 December 2020

Dexfenfluramine and neurotoxicity.

1 reference

12 December 2020

Turnover and oxidation rates of plasma-free fatty acids in obese patients treated with dexfenfluramine

1 reference

12 December 2020

Pulmonary hypertension and fenfluramine

1 reference

12 December 2020

Pharmacotherapy for obesity -- do the benefits outweigh the risks?

1 reference

12 December 2020

Neuroendocrine abnormalities in human obesity

1 reference

12 December 2020

Pulmonary hypertension and dexfenfluramine

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

Dexfenfluramine and abdominal visceral fat

1 reference

12 December 2020

Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man.

1 reference

12 December 2020

Waist circumference as a measure for indicating need for weight management.

1 reference

12 December 2020

Dexfenfluramine and neurotoxicity

1 reference

12 December 2020

Options for the management of obesity

1 reference

12 December 2020

Worldwide epidemiology of obesity

1 reference

12 December 2020

Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.

1 reference

12 December 2020

Treatment of Obese Patients with Dexfenfluramine: A Multicenter, Placebo-Controlled Study

1 reference

12 December 2020

Energy metabolism and metabolite patterns of rats after application of dexfenfluramine

1 reference

12 December 2020

A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors

1 reference

12 December 2020

Familial resemblance in fatness indicators

1 reference

12 December 2020

Dexfenfluramine reduces cardiovascular risk factors

1 reference

12 December 2020

Thermogenesis, brown adipose tissue and dexfenfluramine in animal studies

1 reference

12 December 2020

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine

1 reference

12 December 2020

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

12 December 2020

10.2165/00003495-199652050-00007

Identifiers

DOI

1 reference

PubMed ID

9118819

Dimensions Publication ID

30 September 2017

0 references

1 reference

PubMed ID

9118819